Drug Database
Back to search

Ireland· IE-PA-EU/1/17/1178/010-013

XELJANZ 11 mg film-coated tablets

A atezolizumab product containing tofacitinib, registered in Ireland by Pfizer Europe MA EEIG.

ATC L01XC32

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedXELJANZ 11 mg film-coated tabletsATCL01XC32REGISTER NO.IE-PA-EU/1/17/1178/01…PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tofacitinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

HPRA (Ireland)
Active substance
TOFACITINIB
Manufacturer
Pfizer Europe MA EEIG
Country
Ireland (IE)
ATC code
L01XC32
ATC class
Atezolizumab
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/17/1178/010-013

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

75 interactions on record for atezolizumab.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check atezolizumab against other medicinesHow interaction checks work

Atezolizumab · interactions on record

75 records

  • 30 severe
  • 45 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Atezolizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atezolizumab products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Tofacitinib Devatis, Tofacitinib Stada
  • Bulgaria · Tофацитиниб Devatis
  • Denmark · Tofacitinib Accord, Tofacitinib Newbury
  • Spain · Tofacitinib Stada
  • Finland · Tofacitinib Devatis, Tofacitinib Stada
  • France · Tofacitinib Stada
  • United Kingdom (Northern Ireland) · Tofacitinib Amarox, Tofacitinib Brown & Burk Uk
  • Croatia · Tofacitinib Accord, Tofacitinib Stada
  • Iceland · Xeljanz
  • Liechtenstein · Xeljanz
  • Malta · Tofacitinib Stada
  • Netherlands · Tofacitinib Devatis, Tofacitinib Stada
  • Norway · Tofacitinib Accord, Tofacitinib Devatis
  • Portugal · Tofacitinib Bluepharma
  • Sweden · Tofacitinib Devatis, Tofacitinib Newbury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7dc83db5-752c-471e-8d46-14224f8685c7
GET /v1/drugs/7dc83db5-752c-471e-8d46-14224f8685c7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Prolonged-release tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XC32",
    "L04AA"
  ],
  "strength": null,
  "pa_number": "EU/1/17/1178/010-013",
  "substances": [
    "TOFACITINIB"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "16/12/2019",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about atezolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console